Last updated on July 2019

EpicentRx RRx001-211-01: RRx-001 in Patients with Small Cell Lung Cancer, High-grade Neuroendocrine Carcinoma, EGFR Mutation Positive Non-Small Cell Lung Cancer or Ovarian Cancer (Including Malignant Mixed Mullerian Tumore (MMMT) of the Ovary or Uterus) Previously Treated with a Platinum-based Regimen (QUADRUPLE THREAT)


Brief description of study

EpicentRx RRx001-211-01: RRx-001 in Patients with Small Cell Lung Cancer, High-grade Neuroendocrine Carcinoma, EGFR Mutation Positive Non-Small Cell Lung Cancer or Ovarian Cancer (Including Malignant Mixed Mullerian Tumore (MMMT) of the Ovary or Uterus) Previously Treated with a Platinum-based Regimen (QUADRUPLE THREAT)

Detailed Study Description

EpicentRx RRx001-211-01: RRx-001 in Patients with Small Cell Lung Cancer, High-grade Neuroendocrine Carcinoma, EGFR Mutation Positive Non-Small Cell Lung Cancer or Ovarian Cancer (Including Malignant Mixed Mullerian Tumore (MMMT) of the Ovary or Uterus) Previously Treated with a Platinum-based Regimen (QUADRUPLE THREAT)

Clinical Study Identifier: TX149710

Find a site near you

Start Over

Baptist Health Lexington Clinical Research Center

1740 Nicholasville Road Lexington, KY USA
  Connect »